^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Promune (agatolimod)

    i
    Associations
    News

    Trials

    Company:
    Pfizer
    Drug class:
    TLR9 agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) (NCT04853017)
    Phase 1
    Elicio Therapeutics
    Active, not recruiting
    Last update posted :
    04/15/2024
    Initiation :
    10/04/2021
    Primary completion :
    01/26/2023
    Completion :
    03/01/2026
    KRAS • NRAS
    |
    KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12
    |
    ELI-002 7P • Promune (agatolimod)
    Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    10/29/2012
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    HLA-DRB1
    |
    PD-1 expression
    |
    Promune (agatolimod)
    Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer (NCT00292045)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/04/2023
    Initiation :
    10/27/2004
    Primary completion :
    01/09/2006
    Completion :
    01/09/2006
    CD8 • CTAG1B
    |
    Promune (agatolimod)
    A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer. (NCT00199836)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    09/03/2003
    Primary completion :
    09/05/2005
    Completion :
    06/06/2006
    CD8 • CTAG1B • CTAG2
    |
    HLA-A2 positive
    |
    Promune (agatolimod)
    NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors (NCT00299728)
    Phase 1
    Ludwig Institute for Cancer Research
    Completed
    Last update posted :
    10/10/2022
    Initiation :
    03/21/2006
    Primary completion :
    10/10/2006
    Completion :
    01/10/2014
    CTAG1B • CD4 • CTAG2
    |
    CTAG1B expression • CTAG2 expression
    |
    Promune (agatolimod)
    High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (NCT01266603)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/19/2020
    Initiation :
    02/22/2011
    Primary completion :
    11/01/2018
    Completion :
    11/01/2018
    MAGEA3
    |
    Proleukin (aldesleukin) • Promune (agatolimod) • Zumagev (astuprotimut-R)
    Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL (NCT00490529)
    Phase 2
    Ronald Levy
    Completed
    Last update posted :
    01/13/2020
    Initiation :
    08/01/2009
    Primary completion :
    12/14/2017
    Completion :
    12/14/2017
    CD4
    |
    Rituxan (rituximab) • cyclophosphamide • Neupogen (filgrastim) • Promune (agatolimod) • cyclophosphamide intravenous
    CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors (NCT00819806)
    Phase 1
    Hassane M. Zarour, MD
    Completed
    Last update posted :
    07/31/2017
    Initiation :
    01/01/2009
    Primary completion :
    05/01/2012
    Completion :
    01/01/2015
    CTAG1B
    |
    CTAG1B expression
    |
    cyclophosphamide • Promune (agatolimod) • cyclophosphamide intravenous
    Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma (NCT00438880)
    Phase 1/2
    Mayo Clinic
    Completed
    Last update posted :
    02/04/2016
    Initiation :
    10/01/2004
    Primary completion :
    10/01/2010
    Completion :
    11/01/2014
    CD20
    |
    Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan) • Novex (rituximab biosimilar) • Promune (agatolimod)
    A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer. (NCT00471159)
    Phase 2
    Pfizer
    Withdrawn
    Last update posted :
    05/04/2015
    Initiation :
    08/01/2007
    HER-2
    |
    HER-2 negative
    |
    docetaxel • Promune (agatolimod)